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Abstract 
Background: Malaria in pregnancy has been associated with maternal morbidity, placental malaria, and adverse 
birth outcomes. However, data are limited on the relationships between longitudinal measures of malaria during 
pregnancy, measures of placental malaria, and birth outcomes.
Methods: This is a nested observational study of data from a randomized controlled trial of intermittent preventive 
therapy during pregnancy among 282 participants with assessment of placental malaria and delivery outcomes. HIV-
uninfected pregnant women were enrolled at 12–20 weeks of gestation. Symptomatic malaria during pregnancy was 
measured using passive surveillance and monthly detection of asymptomatic parasitaemia using loop-mediated iso-
thermal amplification (LAMP). Placental malaria was defined as either the presence of parasites in placental blood by 
microscopy, detection of parasites in placental blood by LAMP, or histopathologic evidence of parasites or pigment. 
Adverse birth outcomes assessed included low birth weight (LBW), preterm birth (PTB), and small for gestational age 
(SGA) infants.
Results: The 282 women were divided into three groups representing increasing malaria burden during pregnancy. 
Fifty-two (18.4%) had no episodes of symptomatic malaria or asymptomatic parasitaemia during the pregnancy, 157 
(55.7%) had low malaria burden (0–1 episodes of symptomatic malaria and < 50% of samples LAMP+), and 73 (25.9%) 
had high malaria burden during pregnancy (≥ 2 episodes of symptomatic malaria or ≥ 50% of samples LAMP+). 
Women with high malaria burden had increased risks of placental malaria by blood microscopy and LAMP [aRR 14.2 
(1.80–111.6) and 4.06 (1.73–9.51), respectively], compared to the other two groups combined. Compared with women 
with no malaria exposure during pregnancy, the risk of placental malaria by histopathology was higher among low 
and high burden groups [aRR = 3.27 (1.32–8.12) and aRR = 7.07 (2.84–17.6), respectively]. Detection of placental para-
sites by any method was significantly associated with PTB [aRR 5.64 (1.46–21.8)], and with a trend towards increased 
risk for LBW and SGA irrespective of the level of malaria burden during pregnancy.
Conclusion: Higher malaria burden during pregnancy was associated with placental malaria and together with the 
detection of parasites in the placenta were associated with increased risk for adverse birth outcomes.
Trial Registration Current Controlled Trials Identifier NCT02163447
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Background
Malaria in pregnancy remains a major public health 
problem in many parts of sub-Saharan Africa partly 
because the coverage of malaria control measures is still 
low. The proportion of the population sleeping under an 
ITN and protected by IRS was estimated to be 57% in 
2015 and only 31% of eligible pregnant women received 
three or more doses of IPTp in the same year [1]. In 
2015, an estimated 28 million pregnant women were at 
risk of malaria in this region [1], and several studies have 
shown that the median prevalence of placental malaria is 
26–28% in all pregnant women [2, 3]. Placental malaria is 
associated with adverse birth outcomes such as low birth 
weight (LBW) and preterm birth (PTB) [4, 5]. Approxi-
mately 20% of all LBW deliveries in Africa are attribut-
able to malaria in pregnancy, leading to 75,000–200,000 
infant deaths annually [2, 6]. Furthermore, malaria in 
pregnancy is associated with approximately 36% of all 
preterm births in endemic regions [3].
As most available data are from cross-sectional stud-
ies at the time of delivery, there are limited longitudinal 
data on malaria during pregnancy, and the impact of ges-
tational malaria burden on measures of placental malaria 
and birth outcomes. A prospective study in Benin 
showed an association between microscopic and submi-
croscopic infections (detected by PCR) measured early 
in pregnancy with and increased risk of LBW and PTB, 
respectively [7], but did not investigate the relationship 
between placental malaria and adverse birth outcomes. 
An observational study in Uganda reported that malaria 
in pregnancy (diagnosed by peripheral microscopy) was 
associated with LBW and PTB [8]; however, pregnant 
women often have low levels of parasitaemia that require 
more sensitive molecular methods for detection, such 
as loop-mediated isothermal amplification (LAMP) [9]. 
A Malawian study found an association between sub-
microscopic peripheral malaria diagnosed by qPCR and 
the prevalence of placental malaria, but no associations 
between submicroscopic infection and adverse birth out-
comes [10].
The overall objective of this study was to fill the evi-
dence gap on the relationships between longitudinal 
measures of malaria burden during pregnancy, placental 
malaria and birth outcomes. Factors associated with the 
frequency of symptomatic malaria and asymptomatic 
parasitaemia during pregnancy were examined, and the 
associations between malaria burden and measures of 
placental malaria and adverse birth outcomes assessed.
Methods
Study design, site and population
This was a cohort study that utilized data from a ran-
domized controlled trial of IPTp in Tororo, Uganda. 
Tororo is a rural district in southeastern Uganda with 
an entomologic inoculation rate estimated at 310 infec-
tious bites per person year in 2012 [11]. From June 2014 
to October 2014, 300 pregnant women were enrolled into 
a three-arm, double-blinded, placebo-controlled trial 
of sulfadoxine-pyrimethamine (SP) given every 8  weeks 
versus dihydroartemisinin-piperaquine (DP) given every 
8 weeks versus DP given every 4 weeks for IPTp. Details 
of the parent study have been described elsewhere [12]. 
Briefly, participants were HIV-negative pregnant women 
of at least 16  years of age, with an estimated gestational 
age of 12–20 weeks confirmed by ultrasound. For the pre-
sent study, all 282 women from this cohort with placental 
histopathology and known birth outcomes were included.
Study procedures and follow‑up
At enrollment, pregnant women underwent a standard-
ized history and physical exam including assessment of 
wealth status, gravidity, gestational age by ultrasound, and 
age. Each participant received a long-lasting insecticide-
treated bed net (LLIN). Women received all their medi-
cal care at a designated study clinic that was open daily. 
Routine visits were conducted every 4  weeks, including 
collection of dried blood spots (DBS) for LAMP. Par-
ticipants with positive LAMP results were not treated 
for malaria. Women were also encouraged to present to 
the clinic with any illness. Patients who presented with a 
documented fever (tympanic temperature ≥ 38.0 °C) or a 
history of fever in the prior 24 h had peripheral blood col-
lected for a thick blood smear. If the blood smear was pos-
itive, the patient was diagnosed with symptomatic malaria 
and treated with artemether–lumefantrine. At delivery, a 
standardized assessment was completed including evalu-
ation of infant birth weight and gestational age, and col-
lection of specimens within 1  h of delivery, including 
placental tissue, placental blood smears, and DBS of pla-
cental blood. All women were encouraged to deliver at the 
hospital adjacent to the study clinic. Women delivering 
at home were visited by study staff as close to the time of 
delivery as possible for assessment and sample collection.
Laboratory methods
DBS were tested for the presence of malaria para-
sites using LAMP as previously described [13, 14]. 
Keywords: Malaria, Pregnancy, Placental malaria, Birth outcomes, Asymptomatic parasitaemia, IPTp, Low birth 
weight, Small for gestational age, Preterm birth, LAMP
Page 3 of 11Kapisi et al. Malar J  (2017) 16:400 
Formalin-fixed paraffin-embedded placental biopsies 
were processed in duplicate for histological evidence of 
placental malaria using a standardized case record form 
by two independent readers as previously described [12]. 
A third reader resolved any discrepant results. Blood 
smears were stained with 2% Giemsa and read by two 
trained laboratory technicians. Smears were considered 
negative if no asexual parasites were detected in 100 
high-powered fields. A third reviewer settled any dis-
crepant readings.
Variables of interest
The following demographic data was collected: mater-
nal age, possession of bed net at enrollment, wealth sta-
tus, gravidity, gestational age, and IPTp treatment arm. 
Wealth status was categorized into lowest, middle, and 
highest tertiles designed as a composite variable using 
ownership of several household items and land. Gravidity 
was grouped as primigravidas (1st pregnancy) and multi-
gravidas (≥ 2 pregnancies). Gestational age at enrollment 
was confirmed by ultrasound measurements by fetal 
biometry at less than 20 weeks’ gestation. IPTp treatment 
arm was categorized as SP given every 8 weeks, DP given 
every 8 weeks and DP given every 4 weeks.
Malaria in pregnancy was defined as both sympto-
matic malaria and asymptomatic parasitaemia. Sympto-
matic malaria was measured using passive surveillance 
and defined as fever with positive blood smear. Asymp-
tomatic parasitaemia was measured using active surveil-
lance every 4 weeks and defined as molecular detection 
of malaria parasites from a DBS by LAMP. Measures of 
placental malaria at the time of delivery included: the 
detection of malaria parasites in placental blood by both 
microscopy and LAMP, and histopathologic evidence 
of placental malaria (parasites and/or pigment) from 
placental biopsies. Birth outcomes assessed included: 
LBW (< 2500 g), PTB (< 37 weeks gestational age), and 
SGA (birth weight < 10th percentile for gestational age 
according to East African fetal weight standards) [15]. 
In this study, an East African fetal weight standard was 
used because international growth standards (such as 
the Intergrowth-21st and the WHO growth curves) 
have shown greater variance of estimated fetal weight 
between countries, especially later in gestation [16, 17]. 
Utilizing the composite international standards above 
would have under- (Intergrowth-21st) or over-estimated 
(WHO) the incidence of SGA compared to the East Afri-
can standards. There were eight cases of twin gestation; 
four were monochorionic–diamniotic and four were 
dichorionic–diamniotic. In these cases, outcomes were 
considered positive if present in at least one placenta 
and/or child.
Statistical methods
Data were double entered into a Microsoft Access data-
base. Data analysis was done using Stata 14 (Stata Corp, 
College Station TX). For baseline characteristics, com-
parison of proportions was done using the χ2 test and the 
one way anova test for normally-distributed continuous 
variables. Generalized linear Poisson regression models 
with robust standard errors were used to investigate asso-
ciations between a categorical measure of malaria bur-
den during pregnancy and measures of placental malaria 
as well as associations between a composite measure of 
malaria in pregnancy and adverse birth outcomes. Asso-
ciations were expressed as relative risks. Multivariate 
analyses included adjustment for which drug was given 
for IPTp and gravidity. All p values were two-sided and 
values of < 0.05 were considered statistically significant.
Ethical approval
Informed consent was obtained from all study partici-
pants. Ethical approval was obtained from the Uganda 
National Council of Science and Technology, the Mak-
erere University School of Medicine Research and Ethics 
Committee, the Makerere University School of Biomedi-
cal Sciences Research and Ethics Committee, and the 
University of California, San Francisco, Committee on 
Human Research.
Results
Characteristics of malaria infection status 
during pregnancy
A total of 57/282 (20.2%) women had symptomatic 
malaria during pregnancy. Of these, 44/282 (15.6%) had 
only one episode of symptomatic malaria during preg-
nancy and 13/282 (4.6%) had more than one episode 
(2–3 episodes), resulting in a total of 72 malaria epi-
sodes. Asymptomatic parasitaemia during pregnancy 
was detected by LAMP on DBS in 230/282 (81.6%) of 
women; 162/282 (57.4%) had asymptomatic parasitaemia 
with  <  50% of their monthly DBS samples positive for 
malaria parasites and 68/282 (24.1%) had ≥ 50% of their 
DBS samples positive for malaria parasites.
To investigate the associations between the frequency 
of malaria infection during pregnancy and placental 
malaria, a categorical variable of malaria burden dur-
ing pregnancy was created. Three groups representing 
increasing malaria burden were defined as follows: (1) 
“none” =  women who had no episodes of symptomatic 
malaria or asymptomatic parasitaemia during pregnancy; 
(2) “low”  =  women with 0–1 episode of symptomatic 
malaria and < 50% of DBS samples positive for parasites 
by LAMP during pregnancy; and (3) “high”  =  women 
who had ≥ 2 episodes of symptomatic malaria or ≥ 50% 
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of their DBS samples positive for parasites by LAMP 
during pregnancy (Fig.  1). Based on these definitions, 
there were 52 (18.4%) women with no malaria infection 
detected during pregnancy, 157 (55.7%) women with low 
malaria burden in pregnancy, and 73 (25.5%) women with 
high malaria burden during their pregnancy.
Baseline characteristics of women stratified by malaria 
infection status during pregnancy are presented in 
Table  1. There were no differences in maternal age or 
gestational age at enrollment. Ownership of a long-last-
ing insecticide-treated bed net at enrollment was > 85% 
across all three groups with no statistically significant 
differences and all women were given an LLIN follow-
ing enrollment. The proportion of primigravid women 
increased with higher malaria burden (21.2, 35.0, and 
46.6% in the none, low, and high groups, respectively; 
p = 0.043). Wealth was inversely associated with malaria 
burden during pregnancy—the lowest tertile of wealth 
386 women screened
86 excluded during screening
36 prior SP or anmalarial therapy during pregnancy
25 gestaonal age greater than 20 weeks
11 HIV posive
3 intenon of moving outside of study area
2 gestaonal age less than 12 weeks
2 chronic medical condion
2 less than 16 years of age
1 non-viable pregnancy
1 early or acve labor
1 residence greater than 30 km from clinic
1 does not plan to deliver in the hospital
1 unwilling to avoid medicaons outside protocol
1 does not plan hospital delivery
300 women enrolled
None (n=52)
No malaria diagnosed during 
pregnancy and all samples negave 
for malaria parasites by LAMP
Low (n=157)
< 2 episodes of malaria diagnosed 
during pregnancy and < 50 % of 
samples posive for malaria parasites 
by LAMP
32 with 1 episode of malaria 
125 with no episodes of malaria
(all <50% of samples LAMP posive)
High (n=73)
2-3 episodes of malaria diagnosed 
during pregnancy or > 50 % of 
samples posive for malaria parasites 
by LAMP
13 with 2-3 episodes of malaria
12 with 1 episode of malaria and        
≥ 50 % of samples LAMP posive 
48 with no episodes of malaria and    
≥ 50 % of samples LAMP posive
11 withdrawn before delivery
5 unable to locate for > 60 days
5 moved out of study area
1 became HIV-infected
289 followed to delivery
7 no sample collected for placental histopathology
282 included in final analyses
Fig. 1 Flow of study participants
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had the highest proportion of women with high malaria 
burden (39.7% vs. 32.9% and 27.4% of women in the mid-
dle and highest wealth tertiles, respectively, p =  0.026). 
Malaria burden during pregnancy was also associated 
with assigned IPTp regimens (p  <  0.001), with women 
randomized to SP every 8  weeks having the highest 
burden of malaria and women randomized to DP every 
4 weeks having the lowest burden of malaria.
Associations between malaria infection status 
during pregnancy and measures of placental malaria
Three different methods of measuring placental malaria 
were evaluated: microscopy of placental blood smear, 
LAMP detection of parasite DNA in placental blood, 
and histopathologic detection of malaria infection (pig-
ment or parasites) of placental biopsies. Risks of placen-
tal malaria were: 8/280 women (2.9%) by microscopy of 
placental blood smears, 24/280 women (8.6%) by LAMP 
of placental blood, and 105/282 women (37.2%) by pla-
cental histopathology. All 105 placentas positive by his-
topathology had pigment in fibrin indicative of past 
infection, but only 7 had parasites indicative of concomi-
tant active infection. There were a total of 25 cases of pla-
cental malaria in which parasites were detected by any 
method (Fig.  2). Of the three methods, LAMP was the 
most sensitive in detecting malaria parasites, identifying 
24 of 25 cases (96.0%); placental blood microscopy and 
histopathology each detected seven cases (7/25, 28.0%). 
Six cases were diagnosed by all three methods. One case 
was diagnosed by both histopathology and LAMP, but 
not placental blood smear. Finally, one case was detected 
only by placental blood smear, and not by LAMP or 
histopathology.
Associations between malaria burden during pregnancy, 
gravidity, and IPTp drug regimen with three different defi-
nitions of placental malaria were assessed. For analyses 
when placental malaria was defined as the detection of 
parasites in placental blood by microscopy or LAMP, the 
“none” and low malaria burden groups were combined 
to form the reference group due to small numbers. Uni-
variate analysis showed that high malaria burden during 
pregnancy, primigravidity, and the use of SP for IPTp were 
all associated with an increased risk of placental malaria 
diagnosed by any method (Table 2). On multivariate anal-
ysis, evaluating the independent effects of malaria bur-
den during pregnancy, gravidity, and IPTp drug, women 
with high malaria burden had a 14-fold higher risk of 
Table 1 Characteristics of study participants by infection status during pregnancy
Characteristic Malaria infection status during pregnancy p value
None (n = 52) Low (n = 157) High (n = 73)
Age at enrollment in years, mean (SD) 23.5 (4.1) 22.1 (3.8) 21.0 (4.2) 0.989
Gestational age at enrollment in weeks, mean 15.6 (2.2) 15.2 (2.0) 15.5 (1.9) 0.857
Primigravida, n (%) 11 (21.2%) 55 (35.0%) 34 (46.6%) 0.043
Bed net ownership at enrollment, n (%)
 None 2 (3.9%) 20 (12.7%) 8 (11.0%)
 Untreated net 4 (7.7%) 2 (1.3%) 2 (2.7%) 0.071
 LLIN 46 (88.5%) 135 (86.0%) 63 (86.3%)
Household wealth index, n (%)
 Lowest tertile 13 (25.0%) 54 (34.4%) 29 (39.7%)
 Middle tertile 12 (23.1%) 57 (36.3%) 24 (32.9%) 0.026
 Highest tertile 27 (51.9%) 46 (29.3%) 20 (27.4%)
IPTp treatment arm, n (%)
 SP every 8 weeks 7 (13.5%) 40 (25.5%) 51 (69.9%)
 DP every 8 weeks 18 (34.6%) 53 (33.8%) 17 (23.3%) < 0.001
 DP every 4 weeks 27 (51.9%) 64 (40.8%) 5 (6.9%)
6
17
1
0
0
1
0
Parasites detected 
in placental blood 
by LAMP
Parasites detected 
by histopathology
Parasites detected 
in placental blood 
by microscopy
Fig. 2 Distribution of parasites detected in placental samples based 
on method of detection
Page 6 of 11Kapisi et al. Malar J  (2017) 16:400 
placental malaria by microscopy and a fourfold higher risk 
by LAMP, compared to women with none to low malaria 
burden (aRR 14.2, 95% CI 1.80–111.6, p = 0.01 and aRR 
4.06, 95% CI 1.73–9.51, p = 0.001, respectively; Table 2). 
By histopathology, a clear dose-dependent effect was 
observed, whereby increasing malaria burden was asso-
ciated with higher risks of placental malaria (aRR 3.27, 
95% CI 1.32–8.12, p = 0.01 for low burden and aRR 7.07, 
95% CI 2.84–17.6, p  <  0.001 for high burden; Table  2). 
Primigravidity remained an independent risk factor for 
placental malaria by all methods on multivariate analy-
sis (aRR 9.22, 3.05, and 2.89 for microscopy, LAMP, and 
histopathology, respectively; Table  2). IPTp with SP was 
also an independent risk factor for placental malaria by 
LAMP (aRR 3.86, 95% CI 1.56–9.56, p = 0.003), but not 
for placental malaria diagnosed by blood microscopy 
or histopathology. Findings were similar in a sensitivity 
analysis where women with symptomatic malaria during 
pregnancy were excluded, and associations between the 
proportion of samples with asymptomatic parasitaemia 
and various measures of placental malaria were evaluated 
(Additional file 1: Table S1).
Associations between a composite indicator of malaria 
in pregnancy and adverse birth outcomes
A total of 38 (13.5%) women had LBW infants, 26 (9.2%) 
women delivered preterm, and 57 (20.2%) had infants 
that were SGA. A composite indicator of gestational 
malaria burden and placental malaria was generated to 
explore associations between malaria in pregnancy with 
birth weight, and adverse birth outcomes. Women were 
grouped into the following categories: (1) “none” cat-
egory with no symptomatic or asymptomatic malaria 
and no placental malaria, (2) low malaria burden and no 
placental malaria, (3) high malaria burden and no placen-
tal malaria, (4) any malaria burden (none, low, and high 
combined) and placental malaria with pigment only on 
histopathology, and (5) any malaria burden and placental 
parasites detected (by microscopy, LAMP, or histopathol-
ogy) (Table  3). There were no differences in mean birth 
weights between categories 1–4. However, if parasites 
were detected in the placenta (category 5) mean birth 
weight was significantly lower (2598 vs. 2934, p = 0.02) 
and (2598 vs. 2962, p  =  0.0003) compared to category 
1 or when parasites were not detected in the placenta 
Table 2 Associations between malaria infection status during pregnancy and measures of placental malaria
a Results missing for 2 of the 282 participants
Risk factor Category Risk Univariate Multivariate
RR (95% CI) p value aRR (95% CI) p value
Placental blood positive for malaria parasites by  microscopya (n = 8)
 Malaria burden in pregnancy None 0/52 (0%) Reference group Reference group
Low 1/156 (0.6%)
High 7/72 (9.7%) 20.2 (2.52–162.2) 0.005 14.2 (1.80–111.6) 0.01
 Gravidity Multigravida 1/182 (0.6%) Reference group Reference group
Primigravida 7/98 (7.1%) 13.0 (1.62–104.5) 0.02 9.22 (1.16–73.4) 0.04
 IPTp drug DP 3/184 (1.6%) Reference group Reference group
SP 5/96 (5.2%) 3.19 (0.78–13.1) 0.11 1.16 (0.32–4.15) 0.82
Placental blood positive for malaria parasites by  LAMPa (n = 24)
 Malaria burden in pregnancy None 1/52 (1.9%) Reference group Reference group
Low 5/156 (3.2%)
High 18/72 (25.0%) 8.67 (3.57–21.0) < 0.001 4.06 (1.73–9.51) 0.001
 Gravidity Multigravida 8/182 (4.4%) Reference group Reference group
Primigravida 16/98 (16.3%) 3.71 (1.65–8.38) 0.002 3.05 (1.41–6.62) 0.005
 IPTp drug DP 5/184 (2.7%) Reference group Reference group
SP 19/96 (19.8%) 7.28 (2.80–18.9) < 0.001 3.86 (1.56–9.56) 0.003
Parasites or pigment on placental histopathology (n = 105)
 Malaria burden in pregnancy None 4/52 (7.7%) Reference group Reference group
Low 47/157 (29.9%) 3.89 (1.47–10.3) 0.006 3.27 (1.32–8.12) 0.01
High 54/73 (74.0%) 9.62 (3.71–24.9) < 0.001 7.07 (2.84–17.6) < 0.001
 Gravidity Multigravida 36/182 (19.8%) Reference group Reference group
Primigravida 69/100 (69.0%) 3.49 (2.53–4.81) < 0.001 2.89 (2.12–3.94) < 0.001
 IPTp drug DP 56/184 (30.4%) Reference group Reference group
SP 49/98 (50.0%) 1.64 (1.22–2.21) 0.001 1.02 (0.79–1.32) 0.87
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(categories 1–4) respectively. Furthermore, associations 
between this composite indicator of malaria in preg-
nancy, gravidity, and IPTp drug with adverse birth out-
comes were investigated.
Compared to category 1 (“none” with no evidence of 
placental malaria), there was a non-significant trend 
towards increased risk of LBW, PTB, and SGA in category 
3 (high malaria burden/no placental malaria) in univari-
ate analysis (Additional file 1: Table S2). If parasites were 
detected in the placenta (Category 5), there was a signifi-
cant association with LBW (RR 3.45, 95% CI 1.44–8.23, 
p = 0.005), PTB (RR 7.52, 95% CI 1.72–32.8, p = 0.007), 
and SGA (RR 2.30, 95% CI 1.10–4.80, p  =  0.03) when 
compared to category 1 (Additional file  1: Table S2). 
There was no association with any of the adverse birth 
outcomes when categories 2 (low malaria burden with 
no placental malaria) and 4 (placental malaria with pig-
ment only) were compared with category 1 (Additional 
file 1: Table S2). After adjustment for gravidity and IPTp, 
there still was a non-significant trend towards increased 
risk of LBW, PTB, and SGA in category 3 compared to 
category 1 (Table  3). Amongst women with parasites in 
the placenta, there still was a significant association with 
PTB (aRR 5.88, 95% CI 1.02–34.0, p = 0.048) compared 
to category 1. However, the associations with LBW and 
SGA within this category were not statistically signifi-
cant although there were trends for increased risk for 
LBW and SGA (Table  3). Primigravidity was associated 
with non-significant trends for an increased risk for all 3 
adverse birth outcomes and IPTp drugs were not associ-
ated with any of the adverse birth outcomes.
Discussion
Associations between measures of symptomatic malaria 
and asymptomatic parasitaemia during pregnancy, pla-
cental malaria, and adverse birth outcomes were assessed 
in a well described cohort of Ugandan women enrolled 
in a clinical trial of IPTp. The burden of malaria was high 
in this cohort with asymptomatic parasitaemia detected 
in over 80% of women and over 20% of women having at 
least one episode of symptomatic malaria. Higher malaria 
burden during pregnancy was strongly associated with 
three different measures of placental malaria: the detec-
tion of malaria parasites in placental blood by micros-
copy or LAMP, and histopathologic evidence of placental 
malaria (parasites and/or pigment) from placental biop-
sies. When evaluating associations between a composite 
indicator of malaria in pregnancy and adverse birth out-
comes (LBW, PTB, and SGA), the detection of malaria 
parasites in the placenta was found to be a statistically 
significant risk factor for PTB. However, it should be 
noted that due to the relatively small sample size of some 
categories of malaria in pregnancy, the lack of statistically 
significant associations with adverse birth outcomes may 
have been due to a lack of statistical power.
The results presented here are consistent with prior 
studies that demonstrated an association between 
peripheral parasitaemia during pregnancy and placen-
tal malaria [8, 10, 18]. De Beaudrap et  al. showed that 
peripheral parasitaemia at enrollment (detected by 
rapid diagnostic test and microscopy) and the number 
of symptomatic malaria episodes were most strongly 
associated with placental malaria [8]. Cohee et  al. simi-
larly found that each episode of submicroscopic infection 
increased the risk of placental malaria by nearly fivefold 
[10]. Similarly, women with a high malaria burden during 
pregnancy had a much higher risk of placental malaria 
defined by microscopy, LAMP, or histopathology com-
pared to women with no infections with malaria parasites 
detected or low malaria burden during pregnancy after 
adjusting for IPTp treatment arm and gravidity.
Prior longitudinal studies have also shown associations 
between peripheral Plasmodium falciparum infection 
during pregnancy and adverse pregnancy outcomes, such 
as LBW, PTB, and SGA [7, 8, 18, 19]. These studies have 
consistently found that increasing episodes of malaria 
infection in pregnancy (both submicroscopic and micro-
scopic) are associated with higher risks of decreased birth 
weight. This study builds upon these findings by examin-
ing the relationship between both symptomatic malaria 
and asymptomatic parasitaemia and the intermediary 
effect of placental infection on adverse outcomes.
Associations between the presence of placental malaria 
and an increased risk of LBW and/or PTB have been 
previously reported in several cross-sectional studies [2, 
3, 20, 21]. In this study a composite indicator was gen-
erated which included both measures of malaria burden 
during pregnancy and the presence of malaria pigment or 
parasites in placental samples. When evaluating the asso-
ciations between this composite indicator and adverse 
birth outcomes, the detection of malaria parasites in 
placental samples was significantly associated with PTB 
(aRR  =  5.88) in multivariate analyses and there was a 
non-significant trend towards increased risk for LBW 
and SGA with relative risks of considerable magnitude.
Low birth weight can be due to prematurity, or SGA 
(birth weight below the 10th percentile expected for 
the population at the given gestational age, usually from 
fetal growth restriction), or both. SGA infants have been 
shown to have twice the mortality risk compared to 
appropriate for gestational age infants in low and middle 
income countries, for both preterm and term births [22, 
23]. Furthermore, SGA infants may have an increased 
risk of long-term neuro-cognitive impairment, even in 
term infants [24]. However, studies examining the rela-
tive contributions of LBW, SGA, and PTB in malaria in 
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pregnancy have been sparse [8, 21, 25, 26], as accurate 
determination of gestational age by early ultrasound is 
frequently lacking.
As ultrasound technology has become more widely 
available in malaria-endemic regions, the importance of 
distinguishing between these factors has become more 
apparent. For example, Rijken et al. showed that in a Thai 
population, even treated malaria in pregnancy was asso-
ciated with an increased risk of LBW, PTB, and SGA; 
SGA was present in 5% of malaria-affected pregnan-
cies in non-LBW babies born after 39-weeks of gesta-
tion [27]. Thus, by not considering birth weight adjusted 
for gestational age, the true impact of malaria on preg-
nancy outcomes is underestimated, particularly in term 
pregnancies. Using a growth curve based on an East 
African population [15] in this study, the rate of SGA 
infants was 20.2%, while the rate of LBW and PTB were 
13.5 and 9.2% respectively. The presence of parasites in 
the placenta was associated with a 1.8-fold increased risk 
of SGA in multivariate analysis. Although the detection 
of parasites in the placenta was significantly associated 
with only the adverse birth outcome of preterm delivery, 
caution should be taken in excluding the possibility that 
presence of placental parasites is associated with other 
adverse birth outcomes such as LBW or that other meas-
ures of malaria in pregnancy are associated with adverse 
birth outcomes. For example, women with a high burden 
of malaria during pregnancy but no evidence of placental 
malaria (category 3) had non-significant trends towards 
an increased risk of adverse birth outcomes and the pre-
cision of these estimates were limited by a small sample 
size (n = 18).
Primigravidity is a well-established risk factor for 
increased susceptibility to malaria in pregnancy and 
adverse clinical outcomes [5, 28], consistent with findings 
from this study. Primigravidas had a higher frequency 
of malaria in pregnancy compared to multigravidas, 
were more likely to experience higher malaria burden, 
and had a higher risk of placental malaria at the time of 
delivery. There was also a trend towards increased risk of 
adverse birth outcomes (LBW, PTB, and SGA) in primi-
gravidas, but these associations did not reach statistical 
significance after controlling for a composite indicator 
of malaria in pregnancy probably because of adjustment 
for malaria during pregnancy, which is on the causal 
pathway between gravidity and birth outcome. The gra-
vidity-dependent differences in susceptibility to malaria 
during pregnancy, as well as the risk differences of clini-
cal sequelae, is thought to be related to the development 
of immunity specific to placental malaria in second and 
subsequent pregnancies [29, 30].
Of note, in this study LAMP was used to screen for 
asymptomatic parasitaemia. LAMP is more sensitive 
than microscopy, in both asymptomatic and sympto-
matic cases in pregnancy [9, 31], and so the detection 
threshold is likely lower than previous studies that relied 
primarily on microscopy to detect malaria parasites [8, 
18]. Furthermore, this study also investigated the impact 
of submicroscopic infection in the placenta. Importantly, 
even though this cohort was part of a randomized clini-
cal trial of different IPTp regimens, the women had high 
rates of both asymptomatic parasitaemia and sympto-
matic malaria episodes, especially in the IPTp arm with 
the current WHO standard of three doses of SP as previ-
ously reported [12]. This highlights the need to improve 
current strategies for prevention of malaria in pregnancy, 
and adverse outcomes.
Three methods of detection of placental malaria were 
directly compared: placental blood smear, LAMP of pla-
cental blood, and histopathology. While a high preva-
lence (37%) of placental malaria with only pigment on 
histopathology was observed, this measure was not sig-
nificantly associated with adverse birth outcomes. This 
is not surprising given that pigment in the placenta 
represents prior infection. In contrast, the presence of 
parasites in the placenta, diagnosed by any of the three 
methods, was significantly associated with PTB and 
with an increased risk for LBW and SGA. LAMP was 
the most sensitive of the three, demonstrating that this 
method may provide the optimal diagnostic test for pla-
cental malaria. Additionally, LAMP has clear advantages 
over the other two methods in low resource settings—it 
is easy to learn, does not require specialized equipment, 
and is low cost with rapid results. In contrast, placental 
blood smear is less sensitive (detecting 1/3 of the cases 
diagnosed by LAMP in the study cohort), and placental 
histopathology is resource-intensive and not routinely 
available in malaria-endemic settings.
This study did have limitations. Malaria burden prior to 
enrollment at 12–20 weeks gestation was not evaluated, 
which may have influenced both measures of placental 
malaria and birth outcomes. Other factors that could 
affect fetal growth, birth weight, and prematurity were 
not investigated, such as maternal nutritional status, 
child spacing, maternal anaemia, genetics, other infec-
tions, and smoking. Serial ultrasound examinations dur-
ing the pregnancy were not performed, which could help 
to distinguish constitutionally SGA (for example from 
genetic factors) from SGA due to fetal growth restriction. 
Given the relatively small sample size and low frequency 
of several of the variables of interest, the lack of statisti-
cally significant associations may have been due to insuf-
ficient power rather than true negative findings (type II 
error). However, this study also has several strengths. 
One is the longitudinal design with frequent (monthly) 
measurements of parasitaemia by molecular methods, 
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obstetric dating of gestational age by ultrasound prior to 
20  weeks gestation, and comprehensive analysis of pla-
cental malaria.
Conclusions
Increasing malaria burden in pregnancy was associated 
with primigravidity, lower household wealth, and IPTp 
treatment regimen (especially treatment with SP). Higher 
malaria burden in pregnancy was associated with placen-
tal malaria, and LAMP was the most sensitive measure of 
malaria parasites in the placenta compared with placen-
tal blood microscopy and histopathology. The detection 
of malaria parasites in placental samples was associated 
with an increased risk of adverse birth outcomes.
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